Exelixis Stock Is Down, But Not For Long
Exelixis, Inc. (NASDAQ: EXEL)
Exellixis is having a rough day in the market; and at first glance, it could be cause for concern. However, I’m not concerned at all. The reality is that after presenting overwhelmingly positive Phase 3 data with regard to cabozantinib yesterday, EXEL saw massive gains; ultimately gaining well over 50% in a single day. With that said, it’s important to remember that price movements in the market are a series of overreactions and that it’s natural to see slight corrections to the results of massive growth days. That’s exactly what we’re seeing today. Currently (11:53), EXEL is trading at $5.70 per share after a loss of 2.98% so far today. However, as I said above, I’m not concerned. I’m watching for more massive growth and you should be too!
MannKind Stock Is Confused As To Where To Go
MannKind Corporation (NASDAQ: MNKD)
Yesterday, we saw relatively steep declines in the value of MannKind Corporation’s shares. Today, they are in the red again, but not by nearly as much. Nonetheless, when it comes to MannKind, those who are long on the stock couldn’t care less about the declines. If anything, the declines make them want to buy more shares. The reality is that for most investors in the stock, the value is in Afrezza and technosphere. It’s important to note that Afrezza is still in pre-launch mode and is expected to move into the Direct-to-Consumer phase relatively soon; which many believe will start to drive profit for the stock. The company is also working on new medications that use technosphere; a technology that allows injection only medications to be inhaled. This is also likely to prove to be incredibly profitable in the long run. So, keep your eyes on this one because the lower it goes, the better the opportunity it becomes.
Gilead Sciences Declines Slightly; Adding To The Discount
Gilead Sciences, Inc. (NASDAQ: GILD)
I’ve said it time and time again, Gilead Sciences stock is grossly undervalued; and that’s not hard to see. While most companies are trading around 17 times earnings, and some even higher than that, GILD is currently trading at under 10 times earnings as investors await the results of Q2. Investors are concerned that GILD won’t be able to keep up pace in the HCV market with AbbVie in the mix. However, recent data shows that the company is doing overwhelmingly well. Also, recent regulatory approval in Japan is likely to yield positive results moving forward. I think that when GILD reports Q2 earnings later this month, we’re going to see massive gains as investors realize that the company hasn’t lost its mojo! So, you may want to get in now while there’s still a steep discount on the stock.
Synergy Pharmaceuticals Is Down, But A Catalyst Is Coming
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals is falling in the market today. However, I don’t think that declines are going to last for much longer. A few weeks ago, SGYP announced the commencement of it’s most recent and final study looking into plecanatide for the treatment of IBS-C. If the results from this study prove to be as positive as the results from the past studies, we can expect for the event to act as a catalyst; sending SGYP skyrocketing. So, keep an eye on this one as big movement is coming soon!
Do You Know Of Any Others?
Do you know of any other stocks in biotech that are producing strong opportunities? If so, let us know in the comments below!